A Phase 1 interventional study of VBP15 and Placebo in Healthy, sponsored by ReveraGen BioPharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-10.
Sponsored by ReveraGen BioPharma, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to examine the safety, tolerability, and PK of various increasing single and multiple doses of VBP15 in healthy adult subjects.
ReveraGen BioPharma, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects were orally administered a single dose of VBP15 at 0.1 mg/kg under fasted conditions.
Drug: VBP15
Subjects were orally administered a single dose of VBP15 at 0.3 mg/kg under fasted conditions.
Drug: VBP15
Subjects were orally administered a single dose of VBP15 at 1.0 mg/kg under fasted conditions.
Drug: VBP15
Subjects were orally administered a single dose of VBP15 at 3.0 mg/kg under fasted conditions.
Drug: VBP15
Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg under fasted conditions.
Drug: VBP15
Subjects were orally administered a single dose of VBP15 at 8.0 mg/kg within 30 minutes of beginning a high fat/high high calorie meal.
Drug: VBP15
Subjects were orally administered a single dose of VBP15 at 20.0 mg/kg under fasted conditions.
Drug: VBP15
Subjects were orally administered a placebo under fasted conditions.
Drug: Placebo
Subjects were orally administered VBP15 at 1.0 mg/kg for 14 days under fasted conditions.
Drug: VBP15
Subjects were orally administered VBP15 at 3.0 mg/kg for 14 days under fasted conditions.
Drug: VBP15
Subjects were orally administered VBP15 at 9.0 mg/kg for 14 days under fasted conditions.
Drug: VBP15
Subjects were orally administered VBP15 at 20.0 mg/kg for 14 days under fasted conditions.
Drug: VBP15
Subjects were orally administered placebo for 14 days under fasted conditions.
Drug: Placebo
Number of Subjects With Adverse Effects After a Single Dose of VBP15
Time frame: Participants will be followed for the duration of hospital stay of 4 days
Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)
Time frame: Participants will be followed for the duration of hospital stay of 4 days
Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15
Time frame: Participants will be followed for the duration of hospital stay of 4 days
Number of Subjects With Adverse Effects After 14 Daily Doses of VBP15
Time frame: Participants will be followed for the duration of hospital stay of 15 days
Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose)
Time frame: Participants will be followed for the duration of hospital stay of 15 days
Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15
Time frame: Participants will be followed for the duration of hospital stay of 15 days
In the single ascending dose (SAD) study, subjects were assigned to 1 of 7 dose groups and received a single oral dose of VBP15 or placebo. The multiple ascending dose (MAD) was initiated after a review of safety data from SAD groups. In the MAD study, subjects were randomized to 1 of 4 groups to receive VBP15 or placebo once daily for 14 days
| Milestone | VBP15- 0.1 mg/kg SAD | VBP15- 0.3 mg/kg SAD | VBP15- 1.0 mg/kg SAD | VBP15- 3.0 mg/kg SAD | VBP15- 8.0 mg/kg Fasted SAD | VBP15- 8.0 mg/kg Fed SAD | VBP15- 20.0 mg/kg SAD | Placebo SAD | VBP15- 1.0 mg/kg 14 Day MAD | VBP15- 3.0 mg/kg 14 Day MAD | VBP15- 9.0 mg/kg 14 Day MAD | VBP15- 20 mg/kg 14 Day MAD | Placebo MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 | 6 | 6 | 6 | 8 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 5 | 6 | 6 | 6 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| participants | VBP15- 0.1 mg/kg SAD | VBP15- 0.3 mg/kg SAD | VBP15- 1.0 mg/kg SAD | VBP15- 3.0 mg/kg SAD | VBP15- 8.0 mg/kg Fasting SAD | VBP15- 8.0 mg/kg Fed SAD | VBP15- 20.0 mg/kg SAD | Placebo SAD |
|---|---|---|---|---|---|---|---|---|
| Number of Subjects With Adverse Effects After a Single Dose of VBP15 | 2 | 1 | 1 | 1 | 0 | 1 | 0 | 0 |
| (hr*ng/mL) | VBP15- 0.1 mg/kg SAD | VBP15- 0.3 mg/kg SAD | VBP15- 1.0 mg/kg SAD | VBP15- 3.0 mg/kg SAD | VBP15- 8.0 mg/kg Fasted SAD | VBP15- 8.0 mg/kg Fed SAD | VBP15- 20.0 mg/kg SAD | Placebo SAD |
|---|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose) | 42 ± 17 | 161 ± 16 | 486 ± 20 | 1578 ± 21 | 3997 ± 55 | 10139 ± 25 | 8545 ± 30 | 0 ± 0 |
| (ng/mL) | VBP15- 0.1 mg/kg SAD | VBP15- 0.3 mg/kg SAD | VBP15- 1.0 mg/kg SAD | VBP15- 3.0 mg/kg SAD | VBP15- 8.0 mg/kg Fasting SAD | VBP15- 8.0 mg/kg Fed SAD | VBP15- 20.0 mg/kg SAD | Placebo SAD |
|---|---|---|---|---|---|---|---|---|
| Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15 | 13 ± 13 | 51 ± 17 | 122 ± 33 | 305 ± 24 | 718 ± 43 | 1817 ± 31 | 1648 ± 17 | 0 ± 0 |
| participants | VBP15- 1.0 mg/kg 14 Days MAD | VBP15- 3.0 mg/kg 14 Days MAD | VBP15- 9.0 mg/kg 14 Days MAD | VBP15- 20.0 mg/kg 14 Days MAD | Placebo MAD |
|---|---|---|---|---|---|
| Number of Subjects With Adverse Effects After 14 Daily Doses of VBP15 | 2 | 0 | 0 | 2 | 2 |
| (hr*ng/mL) | VBP15- 1.0 mg/kg 14 Days MAD | VBP15- 3.0 mg/kg 14 Days MAD | VBP15- 9.0 mg/kg 14 Days MAD | VBP15- 20.0 mg/kg 14 Days MAD | Placebo MAD |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve (AUC) After 14 Daily Doses of VBP15 (0 Through 72 Hours Post Dose) | 794 ± 22 | 1494 ± 19 | 4366 ± 20 | 9309 ± 39 | 0 ± 0 |
| (ng/mL) | VBP15- 1.0 mg/kg 14 Days MAD | VBP15- 3.0 mg/kg 14 Days MAD | VBP15- 9.0 mg/kg 14 Days MAD | VBP15- 20.0 mg/kg 14 Days MAD | Placebo MAD |
|---|---|---|---|---|---|
| Peak Plasma Concentration (Cmax) of VBP15 After 14 Daily Doses of VBP15 | 153 ± 16 | 281 ± 37 | 1082 ± 23 | 2416 ± 51 | 0 ± 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VBP15- 0.1 mg/kg SAD | — | 0/6 (0%) | 2/6 (33.3%) |
| VBP15- 0.3 mg/kg SAD | — | 0/6 (0%) | 1/6 (16.7%) |
| VBP15- 1.0 mg/kg SAD | — | 0/6 (0%) | 1/6 (16.7%) |
| VBP15- 3.0 mg/kg SAD | — | 0/6 (0%) | 1/6 (16.7%) |
| VBP15- 8.0 mg/kg Fasted SAD | — | 0/6 (0%) | 0/6 (0%) |
| VBP15- 8.0 mg/kg Fed SAD | — | 0/6 (0%) | 1/6 (16.7%) |
| VBP15- 20.0 mg/kg SAD | — | 0/6 (0%) | 0/6 (0%) |
| Placebo SAD | — | 0/12 (0%) | 0/12 (0%) |
| VBP15- 1.0 mg/kg 14 Days MAD | — | 0/6 (0%) | 2/6 (33.3%) |
| VBP15- 3.0 mg/kg 14 Days MAD | — | 0/6 (0%) | 0/6 (0%) |
| VBP15- 9.0 mg/kg 14 Days MAD | — | 0/6 (0%) | 0/6 (0%) |
| VBP15- 20.0 mg/kg 14 Days MAD | — | 0/6 (0%) | 2/6 (33.3%) |
| Placebo MAD | — | 0/8 (0%) | 2/8 (25%) |
| Event | VBP15- 0.1 mg/kg SAD | VBP15- 0.3 mg/kg SAD | VBP15- 1.0 mg/kg SAD | VBP15- 3.0 mg/kg SAD | VBP15- 8.0 mg/kg Fasted SAD | VBP15- 8.0 mg/kg Fed SAD | VBP15- 20.0 mg/kg SAD | Placebo SAD | VBP15- 1.0 mg/kg 14 Days MAD | VBP15- 3.0 mg/kg 14 Days MAD | VBP15- 9.0 mg/kg 14 Days MAD | VBP15- 20.0 mg/kg 14 Days MAD | Placebo MAD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 1/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| Ear Pain, LeftEar and labyrinth disorders | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| DizzinessNervous system disorders | 0/6 | 1/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 1/8 |
| Non-cardiac chest painGeneral disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| Blood bilirubin, increasedInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| Pain extremity left elbowMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| SyncopeNervous system disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 1/6 | 0/6 | 0/6 | 0/6 | 0/8 |
| Elevated liver enzyme: ALTInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 1/6 | 0/8 |
| Elevated liver enzymesInvestigations | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/12 | 0/6 | 0/6 | 0/6 | 0/6 | 1/8 |
| Age, Categorical(Participants) | VBP15- 0.1 mg/kg SAD | VBP15- 0.3 mg/kg SAD | VBP15- 1.0 mg/kg SAD | VBP15- 3.0 mg/kg SAD | VBP15- 8.0 mg/kg Fasted SAD | VBP15- 8.0 mg/kg Fed SAD | VBP15- 20.0 mg/kg SAD | Placebo SAD | VBP15- 1.0 mg/kg 14 Days MAD | VBP15 - 3.0 mg/kg 14 Days MAD | VBP15- 9.0 mg/kg 14 Days MAD | VBP15- 20.0 mg/kg 14 Days MAD | Placebo MAD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 | 6 | 6 | 6 | 8 | 86 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | VBP15- 0.1 mg/kg SAD | VBP15- 0.3 mg/kg SAD | VBP15- 1.0 mg/kg SAD | VBP15- 3.0 mg/kg SAD | VBP15- 8.0 mg/kg Fasted SAD | VBP15- 8.0 mg/kg Fed SAD | VBP15- 20.0 mg/kg SAD | Placebo SAD | VBP15- 1.0 mg/kg 14 Days MAD | VBP15 - 3.0 mg/kg 14 Days MAD | VBP15- 9.0 mg/kg 14 Days MAD | VBP15- 20.0 mg/kg 14 Days MAD | Placebo MAD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 | 6 | 6 | 6 | 8 | 86 |
| Region of Enrollment(participants) | VBP15- 0.1 mg/kg SAD | VBP15- 0.3 mg/kg SAD | VBP15- 1.0 mg/kg SAD | VBP15- 3.0 mg/kg SAD | VBP15- 8.0 mg/kg Fasted SAD | VBP15- 8.0 mg/kg Fed SAD | VBP15- 20.0 mg/kg SAD | Placebo SAD | VBP15- 1.0 mg/kg 14 Days MAD | VBP15 - 3.0 mg/kg 14 Days MAD | VBP15- 9.0 mg/kg 14 Days MAD | VBP15- 20.0 mg/kg 14 Days MAD | Placebo MAD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 12 | 6 | 6 | 6 | 6 | 8 | 86 |
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Jan 2015, a primary completion of Nov 2015 and a completion of May 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ReveraGen BioPharma, Inc.